ORKA insider trading
HealthcareOruka Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Company website: orukatx.com
ORKA insider activity at a glance
FilingIQ tracks 167 insider transactions for ORKA in filings since Sep 13, 2024. The most recent transaction is dated Oct 1, 2026.
Across the full history, 5 open-market purchases
and 108 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ORKA insider trades is 54.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ORKA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ORKA?
- FilingIQ tracks 167 Form 4 insider transactions for ORKA (Oruka Therapeutics, Inc.), covering filings from Sep 13, 2024 onwards. 68 of those are dated within the last 90 days.
- Are ORKA insiders net buyers or net sellers?
- Across the full Form 4 history for ORKA, 5 transactions (3%) were open-market purchases and 108 (65%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ORKA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ORKA in?
- Oruka Therapeutics, Inc. (ORKA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.58B.
Methodology & sources
Every ORKA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.